BIAL has a new corporate image
BIAL has renewed its corporate identity with a new image and a new claim reflecting BIAL’s positioning, but also the core values and aspirations of the group. The new corporate image is based on the company's commitment to innovation and its path and evolution in recent years. The brand's new signature, Keeping life in mind., common to all markets where BIAL operates, translates the commitment and permanent effort in the search for new therapeutic solutions and the contribution to the improvement of the quality of life and of people's health.
BIAL and Wanbang Announce Exclusive Licensing Agreement for Opicapone in China
BIAL and Wanbang Announce Exclusive Licensing Agreement for Opicapone in China Opicapone is a new treatment for Parkinson’s Disease approved by the European Commission in June 2016 BIAL and Jiangsu Wanbang Biopharmaceutical Group Co., Ltd. (Wanbang), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, SHA: 600196 and HKG: 02196) announced today that they have entered into an exclusive license agreement for the importation, packaging and commercialization of Opicapone in China (excluding Hong Kong, Macao and Taiwan).
BIAL’s medicine for epilepsy approved by the FDA in the USA for paediatrics
The Food & Drug Administration (FDA) – the North-American regulatory authority -, extended the therapeutic indication of the BIAL medicine for epilepsy in the treatment of partial epileptic seizures in children from the age of 4 years. This is FDA’s third approval to BIAL’s antiepileptic. The eslicarbazepine acetate was approved for the first time in 2013 in the USA, as a once-daily adjunctive treatment for patients with partial-onset (focal) seizures with or without secondary generalisation. In 2015, the FDA extended its indication as monotherapy in adults and now the regulatory authority approved eslicarbazepine acetate for the treatment of partial-onset seizures in children.
BIAL at the International Epilepsy Congress
The 32th edition of this Congress took place in Barcelona, from 2nd to 6th of September BIAL attended the 32th International Epilepsy Congress where the most recent data, studies and therapeutics within the area of Epilepsy were discussed. 20 posters on the eslicarbazepine acetate were presented, the first medicine of BIAL’s own research and development for Epilepsy.
BIAL’s new treatment for Parkinson's disease launched in Spain
OPICAPONE HAS NOW BEEN LAUNCHED IN SPAIN FOR THE TREATMENT OF PARKINSON’S DISEASE, BEING ALREADY AVAILABLE IN THE UK AND GERMANY SINCE 2016 Opicapone was authorised by the European Commission in June 2016 as an adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adult patients with Parkinson’s Disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations. Spain is now the third country to market this product, after Germany and the United Kingdom, where it was launched in 2016. Parkinson’s Disease affects about 1.2 million people in Europe, 150.00 of which in Spain, according to the Spanish Parkinson Federation. BIAL believes that in late 2017 and early 2018, it will be possible to start marketing opicapone in other European countries, including Portugal.
BIAL at the 21st International Congress of Parkinson’s Disease and Movement Disorders
The event took place in Vancouver, Canada BIAL attended this Congress with a booth and the presentation of 4 posters on Opicapone, the second medicine of BIAL's own Research & Development for Parkinson’s Disease, which was approved by the European Commission in 2016. This is one of the most relevant events within the area, and it is organized by the International Parkinson and Movement Disorder Society.
European Commission grants Marketing Authorisation for eslicarbazepine acetate as once-daily monotherapy in adults with newly diagnosed partial-onset epilepsy
Bial and Eisai announce that the European Medicines Agency (EMA) has approved eslicarbazepine acetate for use as a once-daily monotherapy to treat adults with newly-diagnosed partial-onset epilepsy. It is already indicated in Europe as adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation. “We are pleased that adults with partial-onset epilepsy across Europe are now able to benefit from a once-daily monotherapy option that is simple to use, which may optimise their adherence,” comments António Portela, CEO of Bial. “Bial has an ongoing commitment to all people living with epilepsy and we look forward to continuing to work with the epilepsy community to bring this new indication to patients.”
BIAL Award 2016 winners
320.000 euros to 4 different works on rheumatic diseases, diabetic foot, cancer and osteoporosis in the 17th edition of the BIAL Award • BIAL Merit Award in Medical Sciences distinguishes Jaime Cunha Branco and co-authors for their work “EpiReumaPt – Epidemiological Study of Rheumatic Diseases in Portugal” • BIAL Award in Clinical Medicine distinguishes the work "Pé Di@bético (Di@betic Foot) – solutions to a major problem", authored by Maria de Jesus Dantas
EPDA CAMPAIGN TO CELEBRATE WORLD PARKINSON’S DAY – APRIL 11 EPDA (European Parkinson Disease Association) launched a campaign on World Parkinson’s Day and BIAL is united for Parkinson. 2017 marks 200 years since Parkinson’s was recognised as a health condition, so BIAL will be focused on this condition and on people living with Parkinson, as it is one of its research areas. #UniteforParkinsons
BIAL takes responsibility for its website contents. By clicking “continue” below, you will be taken to an external website, beyond our responsibility.